NAUT · 10-Q · 2026Q1 · Full report

Manufacturing and Capacity

Nautilus Biotechnology, Inc. · 2026-04-28 · Importance 39 · Surprise 48

To commercialize the Nautilus Voyager platform in volume, the company will need to establish internal manufacturing capacity, contract with manufacturing partners, or both, due to the platform’s complex manufacturing needs. Nautilus notes the manufacturing process will involve many unique precision parts plus production of reagents and antibodies and may encounter unexpected difficulties. The company has highlighted the challenge of sourcing and producing roughly 300 multi-affinity reagents and antibodies necessary for deep proteomic profiling. Management cautions there is no assurance it will be able to build or secure manufacturing partners that meet the required volume and quality for success in the proteomics market.

Key facts

• Nautilus intends to utilize approximately 300 unique multi-affinity reagents and various antibodies in connection with the Nautilus Voyager platform.